Table 1. Combination effect, in vitro, between forms of Selenium and Chemotherapy drugs.

	Chemotherapy	CDDP	DOC	DOX	MIC	SN38	PAX	VP-16
Cell Line
Breast
	MCF-7			MseA/↑ [48], [49]			ySe/± [47]
	MDA-MB-231	S/± [50]	S/± [50]	S/± [50]	S/± [50]	S/± [50]		S/± [50]
	SK-BR-3						ySe/± [47]
Colon
	SW620					S/↑ [50]
	Caco-2						ySe/± [47]
	HCT116					S/↑ [50]
Ovarian
	2008						ySe/± [47]
	Skov3R						MseA/+ [51]
	A2780						MseA/↓ [52]
Prostate
	DU145					MseA/↑ [53]S/± [53]	MseA/↑ [53], [54]S/± [53]	MseA/↑ [53]S/± [53]
	PC3					MseA/↑ [53]S/± [53]	MseA/↑ [53], [54]ySe/± [47]S/± [53]	MseA/↑ [53]S/± [53]
	Pr14							MseA/↑ [55]S/± [55]
	Pr14C1							MseA/↑ [55]S/± [55]
	Pr111							MseA/↑ [55]S/± [55]
	LnCaP						ySe/± [47]
Liver
	HepG2						ySe/± [47]
Intestinal
	HCF8						ySe/± [47]

Legend

↑ Additive effect exists where the Combination Index = 1. In the article, where the authors calculated the CI and the CI was found to be equal to 1.

+ Positive impact – where the use of the two agents in series or combination resulted in increased growth inhibition that was greater than the single agent alone.

/± No impact found.

↓ Negative impact where the use of the two agents in series or combination resulted in decreased growth inhibition versus the drug agent.

CDDP Cisplatin.

DOC Docetaxel.

DOX Doxorubicin.

MIC Mitomycin C.

MSeA Methylselenic Acid.

PAX Paclitaxel.

S Sodium selenite.

SN38 Active metabolite of irinotecan.

VP-16 Etoposide.

ySe Yeast derived selenium.